Disrupting β-amyloid aggregation for Alzheimer disease treatment

Current Topics in Medicinal Chemistry

Volumn 7, Issue 1, 2007, Pages 115-126

  Estrada, L D ^a   Soto, C ^a  

^a UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

Author keywords

sheet breakers; Aggregation inhibitors; Alzheimer's disease; Amyloid

Indexed keywords

1 [6 (2 CARBOXYPYRROLIDIN 1 YL) 6 OXOHEXANOYL]PYRROLIDINE 2 CARBOXYLIC ACID; ALPHA 1 ANTICHYMOTRYPSIN; AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN ANTIBODY; AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; AMYLOID BETA PROTEIN[25-35]; APOLIPOPROTEIN E; BINDING PROTEIN; CLUSTERIN; HOMOTAURINE; LAMININ 1; MEROSIN; PREALBUMIN; PROTEIN INHIBITOR; PROTEOGLYCAN; SERUM AMYLOID P; TAU PROTEIN; UNCLASSIFIED DRUG;

ABSENCE OF SIDE EFFECTS; ALZHEIMER DISEASE; AMYLOIDOSIS; CLINICAL TRIAL; COGNITIVE DEFECT; DEGENERATIVE DISEASE; DRUG DESIGN; DRUG PROTEIN BINDING; DRUG SCREENING; DRUG TARGETING; HUMAN; IMMUNOSTIMULATION; IMMUNOTHERAPY; MENINGOENCEPHALITIS; MOLECULAR MECHANICS; NEUROPATHOLOGY; NONHUMAN; PROTEIN AGGREGATION; PROTEIN FOLDING; PROTEIN PROCESSING; PROTEIN PROTEIN INTERACTION; PROTEIN SYNTHESIS INHIBITION; REVIEW;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; DRUG DESIGN; HUMANS; MODELS, MOLECULAR; PEPTIDES; PROTEIN FOLDING;

EID: 33846054061     PISSN: 15680266     EISSN: None     Source Type: Journal    
DOI: 10.2174/156802607779318262     Document Type: Review

References (151)

1. Khachaturian, Z. S. Diagnosis of Alzheimer's disease. Arch. Neurol. 1985, 42, 1097-1105.
2. Hamos, J. E.; DeGennaro, L. J.; Drachman, D. A. Synaptic loss in Alzheimer's disease and other dementias. Neurology 1989, 39, 355-361.
3. Giacobini, E. Cholinergic foundations of Alzheimer's disease therapy. J. Physiol Paris 1998, 92, 283-287.
4. Katzman, R.; Jackson, J. E. Alzheimer disease: basic and clinical advances. J. Am. Geriatr. Soc. 1991, 39, 516-525.
5. Selkoe, D. J. Alzheimer's disease: genotypes, phenotypes, and treatments. Science 1997, 275, 630-631.
6. Grundke-Iqbal, I.; Iqbal, K.; Quinlan, M.; Tung, Y. C.; Zaidi, M. S.; Wisniewski, H. M. Microtubule-associated protein tau. A component of Alzheimer paired helical filaments. J. Biol. Chem. 1986, 261, 6084-6089.
7. Hardy, J.; Selkoe, D. J. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 2002, 297, 353-356.
8. Glenner, G. G. Amyloid deposits and amyloidosis. The beta-fibrilloses (first of two parts). N. Engl. J. Med. 1980, 302, 1283-1292
9. Sipe, J. D. Amyloidosis. Annu. Rev. Biochem. 1992, 61, 947-975.
10. Carrell, R. W.; Lomas, D. A. Conformational disease. Lancet 1997, 350, 134-138.
11. Dobson, C. M. Protein misfolding, evolution and disease. Trends Biochem. Sci. 1999, 24, 329-332.
12. Soto, C. Protein misfolding and disease; protein refolding and therapy. FEBS Lett. 2001, 498, 204-207.
13. Selkoe, D. J. The origins of Alzheimer disease: a is for amyloid. JAMA 2000, 283, 1615-1617.
14. Hardy, J.; Allsop, D. Amyloid deposition as the central event in the aetiology of Alzheimer's disease. Trends Pharmacol. Sci. 1991, 12, 383-388.
15. Selkoe, D. J. The cell biology of beta-amyloid precursor protein and presenilin in Alzheimer's disease. Trends Cell Biol. 1998, 8, 447-453.
16. Price, D. L.; Sisodia, S. S. Mutant genes in familial Alzheimer's disease and transgenic models. Annu. Rev. Neurosci. 1998, 21, 479-505.
17. Younkin, S. G. Evidence that A beta 42 is the real culprit in Alzheimer's disease. Ann. Neurol. 1995, 37, 287-288.
18. Higgins, L. S. Animal models of Alzheimer's disease. Mol. Med. Today 1999, 5, 274-276.
19. Walter, J.; Kaether, C.; Steiner, H.; Haass, C. The cell biology of Alzheimer's disease: uncovering the secrets of secretases. Curr. Opin. Neurobiol. 2001, 11, 585-590.
20. Selkoe, D. J. The molecular pathology of Alzheimer's disease. Neuron 1991, 6, 487-498.
21. Sisodia, S. S.; Price, D. L. Role of the beta-amyloid protein in Alzheimer's disease. FASEB J. 1995, 9, 366-370.
22. Goate, A.; Chartier-Harlin, M. C.; Mullan, M.; Brown, J.; Crawford, F.; Fidani, L.; Giuffra, L.; Haynes, A.; Irving, N.; James, L.; Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease. Nature 1991, 349, 704-706.
23. Haass, C.; Schlossmacher, M. G.; Hung, A. Y.; Vigo-Pelfrey, C.; Mellon, A.; Ostaszewski, B. L.; Lieberburg, I.; Koo, E. H.; Schenk, D.; Teplow, D. B.; Amyloid beta-peptide is produced by cultured cells during normal metabolism. Nature 1992, 359, 322-325.
24. Seubert, P.; Vigo-Pelfrey, C.; Esch, F.; Lee, M.; Dovey, H.; Davis, D.; Sinha, S.; Schlossmacher, M.; Whaley, J.; Swindlehurst, C.; Isolation and quantification of soluble Alzheimer's beta-peptide from biological fluids. Nature 1992, 359, 325-327.
25. Shoji, M.; Golde, T. E.; Ghiso, J.; Cheung, T. T.; Estus, S.; Shaffer, L. M.; Cai, X. D.; McKay, D. M.; Tintner, R.; Frangione, B.; Production of the Alzheimer amyloid beta protein by normal proteolytic processing. Science 1992, 258, 126-129.
26. Soto, C.; Castano, E. M. The conformation of Alzheimer's beta peptide determines the rate of amyloid formation and its resistance to proteolysis. Biochem. J. 1996, 314 (Pt 2), 701-707.
27. Maggio, J. E.; Mantyh, P. W. Brain amyloid - a physicochemical perspective. Brain Pathol. 1996, 6, 147-162.
28. Soto, C.; Branes, M. C.; Alvarez, J.; Inestrosa, N. C. Structural determinants of the Alzheimer's amyloid beta-peptide. J. Neurochem. 1994, 63, 1191-1198.
29. Teplow, D. B. Structural and kinetic features of amyloid beta-protein fibrillogenesis. Amyloid. 1998, 5, 121-142.
30. Jarrett, J. T.; Berger, E. P.; Lansbury, P. T., Jr. The carboxy terminus of the beta amyloid protein is critical for the seeding of amyloid formation: implications for the pathogenesis of Alzheimer's disease. Biochemistry 1993, 32, 4693-4697.
31. Suzuki, N.; Cheung, T. T.; Cai, X. D.; Odaka, A.; Otvos, L. Jr.; Eckman, C.; Golde, T. E.; Younkin, S. G. An increased percentage of long amyloid beta protein secreted by familial amyloid beta protein precursor (beta APP717) mutants. Science 1994, 264, 1336-1340.
32. Hilbich, C.; Kisters-Woike, B.; Reed, J.; Masters, C. L.; Beyreuther, K. Substitutions of hydrophobic amino acids reduce the amyloidogenicity of Alzheimer's disease beta A4 peptides. J. Mol. Biol. 1992, 228, 460-473.
33. Wood, S. J.; Wetzel, R.; Martin, J. D.; Hurle, M. R. Prolines and amyloidogenicity in fragments of the Alzheimer's peptide beta/A4. Biochemistry 1995, 34, 724-730.
34. el Agnaf, O. M.; Guthrie, D. J.; Walsh, D. M.; Irvine, G. B. The influence of the central region containing residues 19-25 on the aggregation properties and secondary structure of Alzheimer's beta-amyloid peptide. Eur. J. Biochem. 1998, 256, 560-569.
35. Soto, C.; Castano, E. M.; Frangione, B.; Inestrosa, N. C. The Alpha-Helical to Beta-Strand Transition in the Amino-Terminal Fragment of the Amyloid Beta-Peptide Modulates Amyloid Formation. J. Biol. Chem. 1995, 270, 3063-3067.
36. Tjernberg, L. O.; Naslund, J.; Lindqvist, F.; Johansson, J.; Karlstrom, A. R.; Thyberg, J.; Terenius, L.; Nordstedt, C. Arrest of beta-amyloid fibril formation by a pentapeptide ligand. J. Biol. Chem. 1996, 271, 8545-8548.
37. Mullan, M.; Crawford, F. The molecular genetics of Alzheimer's disease. Mol. Neurobiol. 1994, 9, 15-22.
38. Barrow, C. J.; Yasuda, A.; Kenny, P. T.; Zagorski, M. G. Solution conformations and aggregational properties of synthetic amyloid beta-peptides of Alzheimer's disease. Analysis of circular dichroism spectra. J. Mol. Biol. 1992, 225, 1075-1093.
39. Zhang, S.; Iwata, K.; Lachenmann, M. J.; Peng, J. W.; Li, S.; Stimson, E. R.; Lu, Y.; Felix, A. M.; Maggio, J. E.; Lee, J. P. The Alzheimer's peptide a beta adopts a collapsed coil structure in water. J. Struct. Biol. 2000, 130, 130-141.
40. Coles, M.; Bicknell, W.; Watson, A. A.; Fairlie, D. P.; Craik, D. J. Solution structure of amyloid beta-peptide(1-40) in a water-micelle environment. Is the membrane-spanning domain where we think it is? Biochemistty 1998, 37, 11064-11077.
41. Shao, H.; Jao, S.; Ma, K.; Zagorski, M. G. Solution structures of micelle-bound amyloid beta-(1-40) and beta-(1-42) peptides of Alzheimer's disease. J. Mol. Biol. 1999, 285, 755-773.
42. Petkova, A. T.; Ishii, Y.; Balbach, J. J.; Antzutkin, O. N.; Leapman, R. D.; Delaglio, F.; Tycko, R. A structural model for Alzheimer's beta-amyloid fibrils based on experimental constraints from solid state NMR. Proc. Natl. Acad. Sci. USA 2002, 99, 16742-16747.
43. Balbach, J. J.; Petkova, A. T.; Oyler, N. A.; Antzutkin, O. N.; Gordon, D. J.; Meredith, S. C.; Tycko, R. Supramolecular structure in full-length Alzheimer's beta-amyloid fibrils: evidence for a parallel beta-sheet organization from solid-state nuclear magnetic resonance. Biophys. J. 2002, 83, 1205-1216.
44. Antzutkin, O. N.; Leapman, R. D.; Balbach, J. J.; Tycko, R. Supramolecular structural constraints on Alzheimer's beta-amyloid fibrils from electron microscopy and solid-state nuclear magnetic resonance. Biochemistry 2002, 41, 15436-15450.
45. Petkova, A. T.; Buntkowsky, G.; Dyda, F.; Leapman, R. D.; Yau, W. M.; Tycko, R. Solid state NMR reveals a pH-dependent antiparallel beta-sheet registry in fibrils formed by a beta-amyloid peptide. J. Mol. Biol. 2004, 335, 247-260.
46. Walsh, D. M.; Klyubin, I.; Fadeeva, J. V.; Rowan, M. J.; Selkoe, D. J. Amyloid-beta oligomers: their production, toxicity and therapeutic inhibition. Biochem. Soc. Trans. 2002, 30, 552-557.
47. Caughey, B.; Lansbury, P. T. Protofibrils, pores, fibrils, and neurodegeneration: separating the responsible protein aggregates from the innocent bystanders. Annu. Rev. Neurosci. 2003, 26, 267-298.
48. Soto, C. Unfolding the role of Protein Misfolding in Neurodegenerative Diseases. Nature Rev. Neurosci. 2003, 4, 49-60.
49. Harper, J. D.; Lansbury, P. T. Jr. Models of amyloid seeding in Alzheimer's disease and scrapie: mechanistic truths and physiological consequences of the time-dependent solubility of amyloid proteins. Annu. Rev. Biochem. 1997, 66, 385-407.
50. Gajdusek, D. C. Nucleation of amyloidogenesis in infectious and noninfectious amyloidoses of brain. Ann. N. Y. Acad. Sci. 1994, 724, 173-190.
51. Jarrett, J. T.; Lansbury, P. T., Jr. Seeding "one-dimensional crystallization" of amyloid: a pathogenic mechanism in Alzheimer's disease and scrapie? Cell 1993, 73, 1055-1058.
52. Krebs, M. R.; Morozova-Roche, L. A.; Daniel, K.; Robinson, C. V.; Dobson, C. M. Observation of sequence specificity in the seeding of protein amyloid fibrils. Protein Sci. 2004, 13, 1933-1938.
53. O'Nuallain, B.; Williams, A. D.; Westermark, P.; Wetzel, R. Seeding specificity in amyloid growth induced by heterologous fibrils. J. Biol. Chem. 2004, 279, 17490-17499.
54. Lambert, M. P.; Barlow, A. K.; Chromy, B. A.; Edwards, C.; Freed, R.; Liosatos, M.; Morgan, T. E.; Rozovsky, I.; Trommer, B.; Viola, K. L.; Wals, P.; Zhang, C.; Finch, C. E.; Krafft, G. A.; Klein, W. L. Diffusible, nonfibrillar ligands derived from Abetal 42 are potent central nervous system neurotoxins. Proc. Natl. Acad. Sci. (USA) 1998, 95, 6448-6453.
55. Walsh, D. M.; Selkoe, D. J. Oligomers on the brain: the emerging role of soluble protein aggregates in neurodegeneration. Protein Pept Lett. 2004, 11, 213-228.
56. Haass, C.; Steiner, H. Protofibrils, the unifying toxic molecule of neurodegenerative disorders? Nat. Neurosci. 2001, 4, 859-860.
57. Walsh, D. M.; Lomakin, A.; Benedek, G. B.; Condron, M. M.; Teplow, D. B. Amyloid beta-protein fibrillogenesis. Detection of a protofibrillar intermediate. J. Biol. Chem. 1997, 272, 22364-22372.
58. Harper, J. D.; Wong, S. S.; Lieber, C. M.; Lansbury, P. T. Observation of metastable Abets amyloid protofibrils by atomic force microscopy. Chem. Biol. 1997, 4, 119-125.
59. Walsh, D. M.; Hartley, D. M.; Kusumoto, Y.; Fezoui, Y.; Condron, M. M.; Lomakin, A.; Benedek, G. B.; Selkoe, D. J.; Teplow, D. B. Amyloid beta-protein fibrillogenesis. Structure and biological activity of protofibrillar intermediates. J. Biol. Chem. 1999, 274, 25945-25952.
60. Lorenzo, A.; Yankner, B. A. Beta-amyloid neurotoxicity requires fibril formation and is inhibited by congo red. Proc. Natl. Acad. Sci. U S. A 1994, 91, 12243-12247.
61. Pike, C. J.; Burdick, D.; Walencewicz, A. J.; Glabe, C. G.; Cotman, C. W. Neurodegeneration induced by beta-amyloid peptides in vitro: the role of peptide assembly state. J. Neurosci. 1993, 13, 1676-1687.
62. Dickson, D. W.; Yen, S. H. Beta-amyloid deposition and paired helical filament formation: which histopathological feature is more significant in Alzheimer's disease? Neurobiol. Aging 1989, 10, 402-404.
63. Terry, R. D. The pathology of Alzheimer's disease: numbers count. Ann. Neurol. 1997, 41, 7.
64. Soto, C. Plaque busters: strategies to inhibit amyloid formation in Alzheimers disease. Mol. Med. Today 1999, 5, 343-350.
65. Wood, S. J.; MacKenzie, L.; Maleeff, B.; Hurle, M. R; Wetzel, R. Selective inhibition of Abeta fibril formation. J. Biol. Chem. 1996, 271, 4086-4092.
66. Allsop, D.; Howlett, D.; Christie, G.; Karran, E. Fibrillogenesis of beta-amyloid. Biochem. Soc. Trans. 1998, 26, 459-463.
67. Kisilevsky, R.; Lemieux, L. J.; Fraser, P. E.; Kong, X.; Hultin, P. G.; Szarek, W. A. Arresting amyloidosis in vivo using small-molecule anionic sulphonates or sulphates: implications for Alzheime'r disease. Nat. Med. 1995, 1, 143-148.
68. Wang, S. S.; Chen, Y. T.; Chou, S. W. Inhibition of amyloid fibril formation of beta-amyloid peptides via the amphiphilic surfactants. Biochim. Biophys. Acta 2005, 1741, 307-313.
69. Ono, K.; Yoshiike, Y.; Takashima, A.; Hasegawa, K.; Naiki, H.; Yamada, M. Potent anti-amyloidogenic and fibril-destabilizing effects of polyphenols in vitro: implications for the prevention and therapeutics of Alzheimer's disease. J. Neurochem. 2003, 87, 172-181.
70. Ono, K.; Hasegawa, K.; Naiki, H.; Yamada, M. Anti-amyloidogenic activity of tannic acid and its activity to destabilize Alzheimer's beta-amyloid fibrils in vitro. Biochim. Biophys. Acta 2004, 1690, 193-202.
71. Ono, K.; Hasegawa, K.; Naiki, H.; Yamada, M. Curcumin has potent anti-amyloidogenic effects for Alzheimer's beta-amyloid fibrils in vitro. J. Neurosci. Res. 2004, 75, 742-750.
72. Liu, R.; Barkhordarian, H.; Emadi, S.; Park, C. B.; Sierks, M. R. Trehalose differentially inhibits aggregation and neurotoxicity of beta-amyloid 40 and 42. Neurobiol Dis. 2005, 20, 74-81.
73. Namba, Y.; Kawatsu, K.; Izumi, S.; Ueki, A.; Ikeda, K. Neurofibrillary Tangles and Senile Plaques in Brain of Elderly Leprosy Patients. Lancet 1992, 340, 978.
74. Tomiyama, T.; Shoji, A.; Kataoka, K.; Suwa, Y.; Asano, S.; Kaneko, H.; Endo, N. Inhibition of amyloid beta protein aggregation and neurotoxicity by rifampicin. Its possible funcfion as a hydroxyl radical scavenger. J. Biol. Chem. 1996, 271, 6839-6844.
75. Pappolla, M.; Bozner, P.; Soto, C.; Shao, H.; Robakis, N. K.; Zagorski, M.; Frangione, B.; Ghiso, J. Inhibition of Alzheimer beta-fibrillogenesis by melatonin. J. Biol. Chem. 1998, 273, 7185-7188.
76. Salomon, A. R.; Marcinowski, K. J.; Friedland, R. P.; Zagorski, M. G. Nicotine inhibits amyloid formation by the beta-peptide. Biochemistry 1996, 35, 13568-13578.
77. Mook-Jung, I.; Joo, I.; Sohn, S.; Kwon, H. J.; Huh, K.; Jung, M. W. Estrogen blocks neurotoxic effects of beta-amyloid (1-42) and induces neurite extension on B103 cells. Neurosci. Lett. 1997, 235, 101-104.
78. Merlini, G.; Ascari, E.; Amboldi, N.; Bellotti, V.; Arbustini, E.; Perfetti, V.; Ferrari, M.; Zorzoli, I.; Marinone, M. G.; Garini, P.; Interaction of the anthracycline 4′-iodo-4′-deoxydoxorubicin with amyloid fibrils: inhibition of amyloidogenesis. Proc. Natl. Acad, Sci. U. S. A 1995, 92, 2959-2963.
79. Ghanta, J.; Shen, C. L.; Kiessling, L. L.; Murphy, R. M. A strategy for designing inhibitors of beta-amyloid toxicity. J. Biol. Chem. 1996, 271, 29525-29528.
80. Pallitto, M. M.; Ghanta, J.; Heinzelman, P.; Kiessling, L. L.; Murphy, R. M. Recognition sequence design for peptidyl modulators of beta-amyloid aggregation and toxicity. Biochemistry 1999, 38, 3570-3578.
81. Findeis, M. A.; Molineaux, S. M. Design and testing of inhibitors of fibril formation. Methods Enzymol. 1999, 309, 476-488.
82. Findeis, M. A.; Musso, G. M.; Arico-Muendel, C. C.; Benjamin, H. W.; Hundal, A. M.; Lee, J. J.; Chin, J.; Kelley, M.; Wakefield, J.; Hayward, N. J.; Molineaux, S. M. Modified-peptide inhibitors of amyloid beta-peptide polymerization. Biochemistry 1999, 38, 6791-6800.
83. Findeis, M. A.; Lee, J. J.; Kelley, M.; Wakefield, J. D.; Zhang, M. H.; Chin, J.; Kubasek, W.; Molineaux, S. M. Characterization of cholyl-leu-val-phe-phe-ala-OH as an inhibitor of amyloid beta-peptide polymerization. Amyloid. 2001, 8, 231-241.
84. Hughes, E.; Burke, R. M.; Doig, A. J. Inhibition of toxicity in the beta-amyloid peptide fragment beta -(25-35) using N-methylated derivatives: a general strategy to prevent amyloid formation. J. Biol. Chem. 2000, 275, 25109-25115.
85. Gordon, D. J.; Tappe, R.; Meredith, S. C. Design and characterization of a membrane permeable N-methyl amino acid-containing peptide that inhibits Abetal-40 fibrillogenesis. J. Pept. Res. 2002, 60, 37-55.
86. Gordon, D. J.; Meredith S. C. Probing the role of backbone hydrogen bonding in beta-amyloid fibrils with inhibitor peptides containing ester bonds at alternate positions. Biochemistry 2003, 42, 475-485.
87. Doig, A. J.; Hughes, E.; Burke, R. M.; Su, T. J.; Heenan, R. K.; Lu, J. Inhibition of toxicity and protofibril formation in the amyloid-beta peptide beta(25-35) using N-methylated derivatives. Biochem. Soc. Trans. 2002, 30, 537-542.
88. Adessi, C.; Soto, C. Converting a peptide into a drug: strategies to improve stability and bioavailability. Curr. Med. Chem. 2002, 9, 963-978.
89. Blanchard, B. J.; Konopka, G.; Russell, M.; Ingram, V. M. Mechanism and prevention of neurotoxicity caused by beta-amyloid peptides: relation to Alzheimer's disease. Brain Res. 1997, 776, 40-50.
90. Blanchard, B. J.; Hiniker, A. E.; Lu, C. C.; Margolin, Y.; Yu, A. S.; Ingram, V. M. Elimination of Amyloid beta Neurotoxicity. J. Alzheimers. Dis. 2000, 2, 137-149.
91. Soto, C.; Kindy, M. S.; Baumann, M.; Frangione, B. Inhibition of Alzheimer's amyloidosis by peptides that prevent beta-sheet conformation. Biochem. Biophys. Res. Commun. 1996, 226, 672-680.
92. Soto, C.; Sigurdsson, E. M.; Morelli, L.; Kumar, R. A.; Castano, E. M.; Frangione, B. Beta-sheet breaker peptides inhibit fibrillogenesis in a rat brain model of amyloidosis: implications for Alzheimer's therapy. Nat. Med. 1998, 4, 822-826.
93. Sigurdsson, E. M.; Permanne, B.; Soto, C.; Wisniewski, T.; Frangione, B. In vivo reversal of amyloid-beta lesions in rat brain. J. Neuropathol. Exp. Neurol. 2000, 59, 11-17.
94. Permanne, B.; Adessi, C.; Fraga, S.; Frossard, M. J.; Saborio, G. P.; Soto, C. Are beta-sheet breaker peptides dissolving the therapeutic problem of Alzheimer's disease? J. Neural Transm. Suppl 2002, 293-301.
95. Permanne, B.; Adessi, C.; Saborio, G. P.; Fraga, S.; Frossard, M. J.; Van Dorpe, J.; Dewachter, I.; Banks, W. A.; Van Leuven, F.; Soto, C. Reduction of amyloid load and cerebral damage in a transgenic mouse model of Alzheimer's disease by treatment with a beta-sheet breaker peptide. FASEB J. 2002, 16, 860-862.
96. Chacon, M. A.; Barria, M. I.; Soto, C.; Inestrosa, N. C. β-sheet breaker peptide prevents Abeta-induced spatial memory impairments with partial reduction of amyloid deposits. Mol. Psychiatry 2004, 9, 953-961.
97. Evans, K. C.; Berger, E. P.; Cho, C. G.; Weisgraber, K. H.; Lansbury, P. T., Jr. Apolipoprotein E is a kinetic but not a thermodynamic inhibitor of amyloid formation: implications for the pathogenesis and treatment of Alzheimer disease. Proc. Natl. Acad. Sci. USA 1995, 92, 763-767.
98. Matsubara, E.; Soto, C.; Governale, S.; Frangione, B.; Ghiso, J. Apolipoprotein J and Alzheimer's amyloid beta solubility. Biochem. J. 1996, 316 (Pt 2), 671-679.
99. Schwarzman, A. L.; Gregori, L.; Vitek, M. P.; Lyubski, S.; Strittmatter, W. J.; Enghilde, J. J.; Bhasin, R.; Silverman, J.; Weisgraber, K. H.; Coyle, P. K.; Transthyretin sequesters amyloid beta protein and prevents amyloid formation, Proc. Natl. Acad. Sci. USA 1994, 91, 8368-8372.
100. Janciauskiene, S.; Garcia, D. F.; Carlemalm, E.; Dahlback, B.; Eriksson, S. Inhibition of Alzheimer beta-peptide fibril formation by serum amyloid P component. J. Biol. Chem. 1995, 270, 26041-26044.
101. Janciauskiene, S.; Rubin, H.; Lukacs, C. M.; Wright, H. T. Alzheimer's peptide Abetal-42 binds to two beta-sheets of alpha1-antichymotrypsin and transforms it from inhibitor to substrate. J. Biol. Chem. 1998, 273, 28360-28364.
102. Castillo, G. M.; Lukito, W.; Peskind, E.; Raskind, M.; Kirschner, D. A.; Yee, A. G.; Snow, A. D. Laminin inhibition of beta-amyloid protein (Abeta) fibrillogenesis and identification of an Abeta binding site localized to the globular domain repeats on the laminin a chain. J. Neurosci. Res. 2000, 62, 451-462.
103. Bronfman, F. C.; Garrido, J.; Alvarez, A.; Morgan, C.; Inestrosa, N. C. Laminin inhibits amyloid-beta-peptide fibrillation. Neurosci. Lett. 1996, 218, 201-203.
104. Castano, E. M.; Prelli, F.; Wisniewski, T.; Golabek, A.; Kumar, R. A.; Soto, C.; Frangione, B. Fibrillogenesis in Alzheimer's disease of amyloid beta peptides and apolipoprotein E. Biochem. J. 1995, 306 (Pt 2), 599-604.
105. Ma, J.; Yee, A.; Brewer, H. B., Jr.; Das, S.; Potter, H. Amyloid-associated proteins alpha 1-antichymotrypsin and apolipoprotein E promote assembly of Alzheimer beta-protein into filaments. Nature 1994, 372, 92-94.
106. Hamazaki, H. Amyloid P component promotes aggregation of Alzheimer's beta-amyloid peptide. Biochem. Biophys. Res. Commun. 1995, 211, 349-353.
107. Weisgraber, K. H.; Roses, A. D.; Strittmatter, W. J. The role of apolipoprotein E in the nervous system. Curr. Opin. Lipidol. 1994, 5, 110-116.
108. Roses, A. D. Apolipoprotein E alleles as risk factors in Alzheimer's disease. Annu. Rev. Med. 1996, 47, 387-400.
109. Ohm, T. G.; Scharnagl, H.; Marz, W.; Bohl, J. Apolipoprotein E isoforms and the development of low and high Braak stages of Alzheimer's disease-related lesions. Acta Neuropathol. (Berl) 1999, 98, 273-280.
110. Bales, K. R.; Dodart, J. C.; DeMattos, R. B.; Holtzman, D. M.; Paul, S. M. Apolipoprotein E, amyloid, and Alzheimer disease. Mol. Interv. 2002, 2, 363-75, 339.
111. Ohman, T.; Dang, N.; LeBoeuf, R. C.; Furlong, C. E.; Fukuchi, K. Expression of apolipoprotein E inhibits aggregation of the C-terminal fragments of beta-amyloid precursor protein. Neurosci. Lett. 1996, 210, 65-68.
112. Mazur-Kolecka, B.; Frackowiak, J.; Wisniewski, H. M. Apolipoproteins E3 and E4 induce, and transthyretin prevents accumulation of the Alzheimer's beta-amyloid peptide in cultured vascular smooth muscle cells. Brain Res. 1995, 698, 217-222.
113. Games, D.; Adams, D.; Alessandrini, R.; Barbour, R.; Berthelette, P.; Blackwell, C.; Carr, T.; Clemens, J.; Donaldson, T.; Gillespie, F. Alzheimer-type neuropathology in trunsgenic mice overexpressing V717F beta-amyloid precursor protein. Nature 1995, 373, 523-527.
114. Dodart, J. C.; Marr, R. A.; Koistinaho, M.; Gregersen, B. M.; Malkani, S.; Verma, I. M.; Paul, S. M. Gene delivery of human apolipoprotein E alters brain Abeta burden in a mouse model of Alzheimer's disease. Proc. Natl. Acad. Sci. USA 2005, 102, 1211-1216.
115. Golabek, A. A.; Kida, E.; Walus, M.; Perez, C.; Wisniewski, T.; Soto, C. Sodium dodecyl sulfate-resistant complexes of Alzheimer's amyloid beta-peptide with the N-terminal, receptor binding domain of apolipoprotein E. Biophys. J. 2000, 79, 1008-1015.
116. Sadowski, M.; Pankiewicz, J.; Scholtzova, H.; Ripellino, J. A.; Li, Y.; Schmidt, S. D.; Mathews, P. M.; Fryer, J. D.; Holtzman, D. M.; Sigurdsson, E. M.; Wisniewski, T. A synthetic peptide blocking the apolipoprotein E/beta-amyloid binding mitigates beta-amyloid toxicity and fibril formation in vitro and reduces beta-amyloid plaques in transgenic mice. Am. J. Pathol. 2004, 165, 937-948.
117. May, P. C.; Johnson, S. A.; Poirier, J.; Lampert-Etchells, M.; Finch, C. E. Altered gene expression in Alzheimer's disease brain tissue. Can. J. Neurol. Sci. 1989, 16, 473-476.
118. Choi-Miura, N. H.; Ihara, Y.; Fukuchi, K.; Takeda, M.; Nakano, Y.; Tobe, T.; Tomita, M. SP-40,40 is a constituent of Alzheimer's amyloid. Acta Neuropathol. (Berl) 1992, 83, 260-264.
119. Kida, E.; Pluta, R.; Lossinsky, A. S.; Golabek, A. A.; Choi-Miura, N. H.; Wisniewski, H. M.; Mossakowski, M. J. Complete cerebral ischemia with short-term survival in rat induced by cardiac arrest. II. Extracellular and intracellular accumulation of apolipoproteins E and J in the brain. Brain Res. 1995, 674, 341-346.
120. McGeer, P. L.; Kawamata, T.; Walker, D. G. Distribution of clusterin in Alzheimer brain tissue. Brain Res. 1992, 579, 337-341.
121. Pasinetti, G. M.; Johnson, S. A.; Oda, T.; Rozovsky, I.; Finch, C. E. Clusterin (SGP-2): a multifunctional glycoprotein with regional expression in astrocytes and neurons of the adult rat brain. J. Comp Neurol. 1994, 339, 387-400.
122. Matsubara, E.; Frangione, B.; Ghiso, J. Characterization of apolipoprotein J-Alzheimer's A beta interaction. J. Biol. Chem. 1995, 270, 7563-7567.
123. Calero, M.; Rostagno, A.; Matsubara, E.; Zlokovic, B.; Frangione, B.; Ghiso, J. Apolipoprotein J (clusterin) and Alzheimer's disease. Microsc. Res. Tech. 2000, 50, 305-315.
124. Giannakopoulos, P.; Kovari, E.; French, L. E.; Viard, I.; Hof, P. R.; Bouras, C. Possible neuroprotective role of clusterin in Alzheimer's disease: a quantitative immunocytochemical study. Acta Neuropathol. (Berl) 1998, 95, 387-394.
125. DeMattos, R. B.; Cirrito, J. R.; Parsadanian, M.; May, P. C.; O'Dell, M. A.; Taylor, J. W.; Harmony, J. A.; Aronow, B. J.; Bales, K. R.; Paul, S. M.; Holtzman, D. M. ApoE and Clusterin Cooperatively Suppress Abeta Levels and Deposition. Evidence that ApoE Regulates Extracellular Abets Metabolism. In Vivo. Neuron 2004, 41, 193-202.
126. Pepys, M. B.; Baltz, M. L.; De Beer, F. C.; Dyck, R. F.; Holford, S.; Breathnach, S. M.; Black, M. M.; Tribe, C. R.; Evans, D. J.; Feinstein, A. Biology of serum amyloid P component. Ann. N. Y. Acad. Sci. 1982, 389, 286-298.
127. Soto, C.; Ghiso, J.; Frangione, B. Alzheimer's amyloid-β aggregation is modulated by the interaction of multiple factors. Alzheimer's Res. 1997, 3, 215-222.
128. Tennent, G. A.; Lovat, L. B.; Pepys, M. B. Serum amyloid P component prevents proteolysis of the amyloid fibrils of Alzheimer disease and systemic amyloidosis. Proc. Natl. Acad. Sci. USA 1995, 92, 4299-4303.
129. Botto, M.; Hawkins, P. N.; Bickerstaff, M. C.; Herbert, J.; Bygrave, A. E.; McBride, A.; Hutchinson, W. L.; Tennent, G. A.; Walport, M. J.; Pepys, M. B. Amyloid deposition is delayed in mice with targeted deletion of the serum amyloid P component gene. Nat. Med. 1997, 3, 855-859.
130. Pepys, M. B.; Herbert, J.; Hutchinson, W. L.; Tennent, G. A.; Lachmann, H. J.; Gallimore, J. R.; Lovat, L. B.; Bartfai, T.; Alanine, A.; Hertel, C.; Hoffmann, T.; Jakob-Roetne, R.; Norcross, R. D.; Kemp, J. A.; Yamamura, K.; Suzuki, M.; Taylor, G. W.; Murray, S.; Thompson, D.; Purvis, A.; Kolstoe, S.; Wood, S. P.; Hawkins, P. N. Targeted pharmacological depletion of serum amyloid P component for treatment of human amyloidosis. Nature 2002, 417, 254-259.
131. Aksenova, M. V.; Aksenov, M. Y.; Butterfield, D. A.; Carney, J. M. alpha-1-antichymotrypsin interaction with A beta (1-40) inhibits fibril formation but does not affect the peptide toxicity. Neurosci. Lett. 1996, 211, 45-48.
132. Janciauskiene, S.; Eriksson, S.; Wright, H. T. A specific structural interaction of Alzheimer's peptide A beta 1-42 with alpha 1-antichymotrypsin. Nat. Struct. Biol. 1996, 3, 668-671.
133. Nilsson, L. N.; Bales, K. R.; DiCarlo, G.; Gordon, M. N.; Morgan, D.; Paul, S. M.; Potter, H. Alpha-1-antichymotrypsin promotes beta-sheet amyloid plaque deposition in a transgenic mouse model of Alzheimer's disease. J. Neurosci. 2001, 21, 1444-1451.
134. Morgan, C.; Bugueno, M. P.; Garrido, J.; Inestrosa, N. C. Laminin affects polymerization, depolymerization and neurotoxicity of Abeta peptide. Peptides 2002, 23, 1229-1240.
135. Saraiva, M. J. Transthyretin amyloidosis: a tale of weak interactions. FEBS Lett. 2001, 498, 201-203.
136. Snow, A. D.; Mar, H.; Nochlin, D.; Kimata, K.; Kato, M.; Suzuki, S.; Hassell, J.; Wight, T. N. The presence of heparan sulfate proteoglycans in the neuritic plaques and congophilic angiopathy in Alzheimer's disease. Am. J. Pathol. 1988, 133, 456-463.
137. Snow, A. D.; Wight, T. N. Proteoglycans in the pathogenesis of Alzheimer's disease and other amyloidoses. Neurobiol. Aging 1989, 10, 481-497.
138. Castillo, G. M.; Ngo, C.; Cummings, J.; Wight, T. N.; Snow, A. D. Perlecan binds to the beta-amyloid proteins (A beta) of Alzheimer's disease, accelerates A beta fibril formation, and maintains A beta fibril stability. J. Neurochem. 1997, 69, 2452-2465.
139. McLaurin, J.; Franklin, T.; Zhang, X.; Deng, J.; Fraser, P. E. Interactions of Alzheimer amyloid-beta peptides with glycosaminoglycans effects on fibril nucleation and growth. Eur. J. Biochem. 1999, 266, 1101-1110.
140. Geerts, H. NC-531 (Neurochem). Curr. Opin. Investig. Drugs 2004, 5, 95-100.
141. Schenk, D.; Barbour, R.; Dunn, W.; Gordon, G.; Grajeda, H.; Guido, T.; Hu, K.; Huang, J.; Johnson-Wood, K.; Khan, K.; Kholodenko, D.; Lee, M.; Liao, Z.; Lieberburg, I.; Mutter, R.; Mutter, L.; Soriano, F.; Shopp, G.; Vasquez, N.; Vandevert, C.; Walker, S.; Wogulis, M.; Yednock, T.; Games, D.; Seubert, P. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 1999, 400, 173-177.
142. Bard, F.; Cannon, C.; Barbour, R.; Burke, R. L.; Games, D.; Grajeda, H.; Guido, T.; Hu, K.; Huang, J.; Johnson-Wood, K.; Khan, K.; Kholodenko, D.; Lee, M.; Lieberburg, I.; Motter, R.; Nguyen, M.; Soriano, F.; Vasquez, N.; Weiss, K.; Welch, B.; Seubert, P.; Schenk, D.; Yednock, T. Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat. Med. 2000, 6, 916-919.
143. Pfeifer, M.; Boncristiano, S.; Bondolfi, L.; Stalder, A.; Deller, T.; Staufenbiel, M.; Mathews, P. M.; Jucker, M. Cerebral hemorrhage after passive anti-Abeta immunotherapy. Science 2002, 298, 1379.
144. Bayer, A. J.; Bullock, R.; Jones, R. W.; Wilkinson, D.; Paterson, K. R.; Jenkins, L.; Millais, S. B.; Donoghue, S. Evaluation of the safety and immunogenicity of synthetic Abeta42 (AN1792) in patients with AD. Neurology 2005, 64, 94-101.
145. Orgogozo, J. M.; Gilman, S.; Dartigues, J. F.; Laurent, B.; Puel, M.; Kirby, L. C.; Jouanny, P.; Dubois, B.; Eisner, L.; Flitman, S.; Michel, B. F.; Boada, M.; Frank, A.; Hock, C. Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization. Neurology 2003, 61, 46-54.
146. Hock, C.; Konietzko, U.; Streffer, J. R.; Tracy, J.; Signorell, A.; Muller-Tillmanns, B.; Lemke, U.; Henke, K.; Moritz, E.; Garcia, E.; Wollmer, M. A.; Umbricht, D.; de Quervain, D. J.; Hofmann, M.; Maddalena, A.; Papassotiropoulos, A.; Nitsch, R. M. Antibodies against beta-amyloid slow cognitive decline in Alzheimer's disease. Neuron 2003, 38, 547-554.
147. Spinney, L. Update on Elan vaccine for Alzheimer's disease. Lancet Neurol. 2004, 3, 5.
148. Nicoll, J. A.; Wilkinson, D.; Holmes, C.; Steart, P.; Markham, H.; Weller, R. O. Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report. Nat. Med. 2003, 9, 448-452.
149. Agadjanyan, M. G.; Ghochikyan, A.; Petrushina, I.; Vasilevko, V.; Movsesyan, N.; Mkrtichyan, M.; Saing, T.; Cribbs, D. H. Prototype Alzheimer's disease vaccine using the immunodominant B cell epitope from beta-amyloid and promiscuous T cell epitope pan HLA DR-binding peptide. J. Immunol. 2005, 174, 1580-1586.
150. Sigurdsson, E. M.; Knudsen, E.; Asuni, A.; Fitzer-Attas, C.; Sage, D.; Quartermain, D.; Goni, F.; Frangione, B.; Wisniewski, T. An attenuated immune response is sufficient to enhance cognition in an Alzheimer's disease mouse model immunized with amyloid-beta derivatives. J. Neurosci. 2004, 24, 6277-6282.
151. Kim, H. D.; Cao, Y.; Kong, F. K.; Van Kampen, K. R.; Lewis, T. L.; Ma, Z.; Tang, D. C.; Fukuchi, K. Induction of a Th2 immune response by co-administration of recombinant adenovirus vectors encoding amyloid beta-protein and GM-CSF. Vaccine 2005, 23, 2977-2986.